DNP treatment also prevents NAFLD (Non-Alcoholic Fatty Liver Disease) development in rats by reducing fasting plasma glucose as well as concentrations of non-esterified fatty acids and insulin, accompanied by a 50–90% decrease in TAG concentrations in plasma, liver, and skeletal muscle [277]. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.